Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Google Secures Pentagon AI Deal for Classified Projects 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
CAMBRIDGE, Mass., Feb. 11, 2016 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, February 18, 2016, at 8:30 a.m. ET to report its fourth quarter and full year 2015 financial results and discuss recent clinical development and corporate activities.
The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 40733168. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Contact: Renee Leck, Senior Manager, Investor and Public Relations [email protected] 617-649-8299
